Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Amortizatization of Intangibles (2024 - 2025)

Historic Amortizatization of Intangibles for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Indivior Pharmaceuticals' Amortizatization of Intangibles fell 5000.0% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 2727.27%. This contributed to the annual value of $8.0 million for FY2024, which is 1111.11% down from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Amortizatization of Intangibles of $2.0 million as of Q3 2025, which was down 5000.0% from $4.0 million recorded in Q3 2024.
  • Indivior Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $4.0 million during Q3 2024, with a 5-year trough of $1.0 million in Q3 2023.
  • Its 4-year average for Amortizatization of Intangibles is $2.3 million, with a median of $2.0 million in 2022.
  • In the last 5 years, Indivior Pharmaceuticals' Amortizatization of Intangibles tumbled by 5000.0% in 2023 and then soared by 30000.0% in 2024.
  • Indivior Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $2.0 million in 2022, then surged by 50.0% to $3.0 million in 2023, then soared by 33.33% to $4.0 million in 2024, then crashed by 50.0% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles stands at $2.0 million for Q3 2025, versus $4.0 million for Q3 2024 and $2.0 million for Q2 2024.